Skip to main content

CORRECTION article

Front. Pharmacol., 28 September 2018
Sec. Translational Pharmacology
Volume 9 - 2018 | https://doi.org/10.3389/fphar.2018.01102

Corrigendum: Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT3 Antagonist, Palonosetron and With the NK1 Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew)

This article is a correction to:

  1. Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT3 Antagonist, Palonosetron and With the NK1 Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew)

    1. Read original article
\r\nJohn A. Rudd,*John A. Rudd1,2*Sze W. ChanSze W. Chan3Man P. NganMan P. Ngan1Longlong TuLonglong Tu1Zengbing LuZengbing Lu1Claudio GiulianoClaudio Giuliano4Emanuela LovatiEmanuela Lovati4Claudio PietraClaudio Pietra4
  • 1Emesis Research Group, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong
  • 2Brain and Mind Institute, The Chinese University of Hong Kong, Shatin, Hong Kong
  • 3School of Health Sciences, Caritas Institute of Higher Education, Tseung Kwan O New Town, Hong Kong
  • 4Helsinn Healthcare SA, Research and Development, Lugano, Switzerland

A Corrigendum on
Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT3 Antagonist, Palonosetron and With the NK1 Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew)

by Rudd, J. A., Chan, S. W., Ngan, M. P., Tu, L., Lu, Z., Giuliano, C., et al. (2018). Front. Pharmacol. 9:869. doi: 10.3389/fphar.2018.00869

An author name was incorrectly spelled as Zhengbing Lu. The correct spelling is Zengbing Lu. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: ghrelin, HM01, nausea, emesis, chemotherapy, motion

Citation: Rudd JA, Chan SW, Ngan MP, Tu L, Lu Z, Giuliano C, Lovati E and Pietra C (2018) Corrigendum: Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HT3 Antagonist, Palonosetron and With the NK1 Antagonist, Netupitant, Against Cisplatin- and Motion-Induced Emesis in Suncus murinus (House Musk Shrew). Front. Pharmacol. 9:1102. doi: 10.3389/fphar.2018.01102

Received: 04 September 2018; Accepted: 10 September 2018;
Published: 28 September 2018.

Approved by: Frontiers in Pharmacology Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2018 Rudd, Chan, Ngan, Tu, Lu, Giuliano, Lovati and Pietra. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: John A. Rudd, jar@cuhk.edu.hk

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.